

## Supporting Information

### **Mucosal-associated invariant T (MAIT) cells are reduced and dysfunctional in acute melioidosis**

Fazle Rabbi Chowdhury<sup>1,2,3,4</sup>, Martha Zewdie<sup>1,2</sup>, Priyanka Abraham<sup>1,2,4</sup>, Srija Moulik<sup>1,2</sup>, Hadiza Adebawale<sup>1,2</sup>, Jennifer Hill<sup>1,2</sup>, Md Robed Amin<sup>5,6</sup>, Lovely Barai<sup>7</sup>, Md Rokibul Hasan<sup>7</sup>, Ayako Kurioka<sup>1</sup>, Patpong Rongkard<sup>1,2</sup>, Direk Limmathurotsakul<sup>4,8</sup>, Nicholas PJ Day<sup>4</sup>, Parinya Chamnan<sup>9</sup>, Paul Klenerman<sup>1,10,11,12</sup>, Chris B Willberg<sup>1</sup>, Barbara Kronsteiner<sup>1,2,\*</sup>, Susanna J Dunachie<sup>1,2,4,10,\*</sup>

<sup>1</sup> Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, United Kingdom.

<sup>2</sup> NDM Centre for Global Health Research, University of Oxford, Oxford, United Kingdom.

<sup>3</sup> Department of Internal Medicine, Bangladesh Medical University, Dhaka, Bangladesh

<sup>4</sup> Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand.

<sup>5</sup> Department of Medicine, Dhaka Medical College, Dhaka, Bangladesh

<sup>6</sup> Directorate General of Health Services, Dhaka, Bangladesh

<sup>7</sup> Department of Microbiology, BIRDEM General Hospital, Dhaka, Bangladesh

<sup>8</sup> Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand


<sup>9</sup> Cardiometabolic Research Group, Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand

<sup>10</sup> Oxford University Hospitals NHS Foundation Trust, Oxford, UK


<sup>11</sup> Translational Gastroenterology Unit, University of Oxford, UK

<sup>12</sup> NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK


\*These authors contributed equally



**Supplementary Figure 1.** MAIT cell frequency is reduced in acute melioidosis. Frequency of CD8<sup>+</sup> and double negative (DN) MAIT cells within live cells was compared between controls, acute melioidosis patients and those who had recovered from melioidosis (1 year post admission). Grey circles: controls, orange squares: acute patients, brown triangles: recovered patients. The number of biological replicates per group is given in brackets under graphs. A two-tailed p value of <0.05 was considered statistically significant. Exact p values <0.1 are displayed on graphs. The data are displayed as median and interquartile range. The three groups were compared using Kruskal Wallis test followed by Dunn's multiple comparison.



**Supplementary Figure 2.** MAIT cell function in melioidosis. Expression of IFN- $\gamma$  in MAIT cells (CD8<sup>+</sup> and DN) upon *in vitro* stimulation with fixed *E. coli*, *B. pseudomallei* (BP), staphylococcal enterotoxin B (SEB) and media was assessed in (A) healthy controls, (B) acute melioidosis patients and (C) those who had recovered from melioidosis (1 year post admission). A two-tailed p value of <math><0.05</math> was considered statistically significant. Exact p values <math><0.1</math> are displayed on graphs. The data are displayed as median and interquartile range. The four treatment groups were compared using Kruskal Wallis test followed by Dunn's multiple comparison.



**Supplementary Figure 3.** Reduced MAIT function is common in Gram-negative sepsis. IFN- $\gamma$  expression in the combined CD8<sup>+</sup> and DN MAIT cell population was compared between patients with acute sepsis caused by different Gram-negative bacteria (*E. coli* n=6, *S. Typhi* n=4, *K. pneumoniae* n=3), healthy controls (n=6) and non-infectious (NI) critically ill cases (n=4) upon stimulation with the respective causative bacteria (fixed). A two-tailed p value of <0.05 was considered statistically significant. Exact p values <0.1 are displayed on graphs. The data are displayed as median and interquartile range. Three or more groups were compared using Kruskal Wallis test followed by Dunn's multiple comparison.

**Supplementary Table 1.** Details of antibodies used for flow cytometry experiments

Marker	Fluorochrome	Clone	Manufacturer	Panel	Figure
CD3	PE-Cy5	UCHT1	Biolegend	Phenotyping and MAIT cytokine secretion assay	Figure 2-4
CD3	eFluor450	OKT3	eBioscience	MAIT cytokine secretion assay	Figure 1
CD4	V450	L200	BD Biosciences	Phenotyping and MAIT cytokine secretion assay	Figure 2-4
CD4	VioGreen	VIT4	Miltenyi Biotec	MAIT cytokine secretion assay	Figure 1
CD8	BV510	RPA-T8	Biolegend	Phenotyping and MAIT cytokine secretion assay	Figure 2-4
CD8	PE-Vio770	BW135/80	Miltenyi Biotec	MAIT cytokine secretion assay	Figure 1
CD161	PE	191B8	Miltenyi Biotec	Phenotyping and MAIT	Figure 1-4

				cytokine secretion assay	
TCR V $\alpha$ 7.2	APC	3C10	Biologend	Phenotyping and MAIT cytokine secretion assay	Figure 1-4
CD69	PE-Vio770	FN50	Miltenyi Biotec	Phenotyping	Figure 2-4
GzmB	FITC	GB11	Biologend	Phenotyping	Figure 2-4
IFN- $\gamma$	PE-Cy7	4S.B3	Biologend	MAIT cytokine secretion assay	Figure 2-4
IFN- $\gamma$	FITC	45-15	Miltenyi Biotec	MAIT cytokine secretion assay	Figure 1
TNF	FITC	MAB11	eBioscience	MAIT cytokine secretion assay	Figure 2-4
TNF	PerCP-Cy5.5	MAB11	Biologend	MAIT cytokine secretion assay	Figure 1

**Supplementary Table 2.** Demographic and clinical characteristics of acute melioidosis patients who survived and died within 28-days of admission

	<b>Survived N=30</b>	<b>Died N=25</b>	<b>p-value*</b>
<b>Age, years</b>			0.13
Median age	63	57	
Age range	44-80	33-84	
Interquartile range	53-70	50-62	
<b>Sex, n (%)</b>			0.3
Female	7 (23%)	9 (36%)	
Male	23 (77%)	16 (64%)	
<b>DM Status, n (%)</b>			0.55
DM	18 (60%)	13 (52%)	
Non-DM	12 (40%)	12 (48%)	
<b>Bacteremic, n (%)</b>	15 (50%)	24 (96%)	<0.001

\*Pearson Chi-Squared test; Mann-Whitney U test; Fisher's exact test

**Supplementary Table 3.** Demographic and clinical characteristics of acute melioidosis patients with and without DM

	<b>DM N=31</b>	<b>Non-DM N=24</b>	<b>p-value*</b>
<b>Age</b>			0.021
Median age	57	63	
Age range	43-80	33-84	
Interquartile range	49-62	57-71	
<b>Sex, n (%)</b>			0.074
Female	12 (39%)	4 (17%)	
Male	19 (61%)	20 (83%)	
<b>28-Day Mortality, n (%)</b>			0.55
Survived	18 (58%)	12 (50%)	
Died	13 (42%)	12 (50%)	
<b>History of renal impairment, n (%)</b>	6 (19%)	5 (31%)	0.47
<b>HbA1c</b>			<0.001
Median (Q1-Q3)	11.10 (8.6-12.6)	5.8 (5.3- 6.2)	

\*Pearson Chi-Squared test; Mann Whitney U test; Fisher's exact test